Login

Login

Generate password

Change password

Forgot Customer Code

Would you like to create a personalised login id for logging in to Emkay Website ?

Change Personalised Login ID

Aurobindo Pharma Ltd.

NSE : AUROPHARMAEQ BSE : 524804 ISIN CODE : INE406A01037Industry : Pharmaceuticals

News

  • Aurobindo Pharma - Intimation Regarding A Safety Incident On April 27, 2025, At Lyfius Pharma Private Limited (A Wholly Owned 28 Apr 2025 | 18:57 | Dion Global

    Intimation of fire accident at Lyfius Pharma Private Limited a wholly owned step down subsidiary of the Company.more...

  • Aurobindo Pharma - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 28 Apr 2025 | 16:49 | Dion Global

    Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Aurobind...more...

  • Aurobindo Pharma - Press Release 26 Apr 2025 | 09:36 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 26 2025 titled CuraTeQ Biologics s.r.o a wholly owned step-d...more...

  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release 26 Apr 2025 | 09:33 | Dion Global

    Submission of Press Release that is being issue by Curateq Biologics s .r.o a wholly owned step down subsidiary of the Company in connection...more...

  • Eugia Pharma gets USFDA nod for dasatinib tablets 23 Apr 2025 | 11:48 | Dion Global

    Aurobindo Pharma Limited announced that its wholly owned subsidiary Eugia Pharma Specialities Limited has received final approval from the U.S. Food ...more...

  • Aurobindo Pharma - Press Release 23 Apr 2025 | 11:24 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 23 2025 titled Eugia Pharma receives USFDA approval...more...

  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release 23 Apr 2025 | 11:21 | Dion Global

    Submission of Press Release that is being issued in connection with the receipt of USFDA approval for Dasatinib Tablets by Eugia Pharma Specialities ...more...

  • Aurobindo Pharma has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025 15 Apr 2025 | 18:50 | Dion Global

    As of March 2025 51.82% is owned by Promoters and 48.18% by Public. Among Promoters holding Indian Promoters holds 48.75% and Foreign Promot...more...

  • Aurobindo Pharma - Press Release 12 Apr 2025 | 21:21 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 12 2025 titled Aurobindo Pharma receives final ANDA approval...more...

  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Apr 2025 | 21:17 | Dion Global

    Submission of press release on receipt of final ANDA approval for RivaroxavanTablets USP.more...

  • Aurobindo Pharma - General Updates 11 Apr 2025 | 14:29 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange about General Updatesmore...

  • Aurobindo Pharma - Completion Of US FDA Inspection At Raleigh Plant, North Carolina, Owned By Aurolife Pharma LLC, A Wholly O 11 Apr 2025 | 14:27 | Dion Global

    Intimation of completion of US FDA inspection at Raleigh Plant North Carolina owned by Aurolife Pharma LLC a wholly owned stepdown subsidiar...more...

  • Aurobindo Pharma - Press Release 09 Apr 2025 | 17:24 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 09 2025 titled CuraTeQ Biologics completes a successful Phas...more...

  • Aurobindo Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release 09 Apr 2025 | 17:21 | Dion Global

    Submission of press release being issued by the Company.more...

  • Aurobindo Pharma - General Updates 05 Apr 2025 | 14:35 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange about General Updatesmore...

  • Aurobindo Pharma - Curateq Biologics Received Marketing Authorization For Dyrupeg™, A Pegylated Filgrastim Biosimilar 05 Apr 2025 | 14:32 | Dion Global

    Intimation of receipt of Marketing authorisation by Curateq Biologics s.r.o a wholly owned step down subsidiary of the Company.more...

  • Aurobindo Pharma - Curateq Biologics Received Marketing Authorization For DyrupegT, A Pegylated Filgrastim Biosimilar 05 Apr 2025 | 14:32 | Dion Global

    Intimation of receipt of Marketing authorisation by Curateq Biologics s.r.o a wholly owned step down subsidiary of the Company.more...

  • Aurobindo Pharma - Certificate under SEBI (Depositories and Participants) Regulations, 2018 02 Apr 2025 | 16:17 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations 2018more...

  • Aurobindo Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 02 Apr 2025 | 16:13 | Dion Global

    Submission of Certificate under regulation 74 (5) of SEBI (DP) Regulations for the Quarter ended March 31 2025more...

  • Aurobindo Pharma - General Updates 31 Mar 2025 | 12:40 | Dion Global

    Aurobindo Pharma Limited has informed the Exchange about General Updatesmore...

Enter Stock

DOW Jones40280.940.42%
Nasdaq17388.710.03%
S&P 5005536.520.20%
Nikkei 22535839.990.38%
Hang Seng22027.890.21%
Shanghai Composite3288.41-0.20%
Sensex80218.371.27%
NSE Index24328.51.20%
BSE 100LCTMC8972.671.24%
BSE Auto 500621.65%
BSE Bharat228402.691.60%
BSE CPSE 3692.441.98%

Commodity

Gold95244-0.50%
Silver974420.01%
Copper820.15101.12%
Crude Oil64130.66%
Lead192.443.15%
Mentha Oil1067.40.96%
Nickel2480223.38%

Currency

USD/INR 85.58(0.08 %)
GBP/INR 113.82(0.25 %)
EUR/INR 97.12(0.07 %)
JPY/INR 0.60(-0.48 %)
CAD/INR 61.57(-0.28 %)
HKD/INR 11.01(-0.09 %)